Telitacicept not checked

RemeGen · RC18 · RC18 240 mg

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 3 trial completes
Trials
3 active
16 in total
Targets
 

What this is

How it works
A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
How it’s given
“The dosage is administered based on the subject's age and baseline body weight.”In the company’s words, NCT07249632 on ClinicalTrials.gov
Tested for
Primary IgA Nephropathy, Myasthenia Gravis, Ocular, CTD-ILD
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with renin-angiotensin system(RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).”In the company’s words, NCT05799287 on ClinicalTrials.gov
Other names
RC18 · RC18 240 mg · RC18 160 mg · RC 18 80 mg · MTX=Methotrexate · Standard therapy

Other drugs for Primary IgA Nephropathy

All 39 drugs for Primary IgA Nephropathy

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Jun 2026 A Study of Telitacicept for IgA Nephropathy (TELIGAN)
Phase 3Recruiting 31 Dec 2026 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Phase 3Not yet recruiting 31 May 2029 Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease
Phase 3Completed 24 Apr 2022 Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
Phase 3Completed 19 Nov 2022 A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
Phase 3Completed 29 Oct 2024 A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
Phase 3Completed 26 Nov 2024 Study of Telitacicept in Generalized Myasthenia Gravis
Phase 3Terminated 3 Apr 2026 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
Phase 2Completed 20 May 2021 A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
Phase 2Completed 23 Jun 2021 A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
Phase 2Completed 14 Jan 2022 A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
Phase 2Terminated 9 Nov 2023 A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
Phase 2Unknown Dec 2025 A Study of Telitacicept in Lupus Nephritis
Phase 2Terminated 3 Apr 2026 RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial
Phase 1Completed 25 Oct 2023 Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
Phase 1Completed 14 Nov 2025 A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Telitacicept

Following is part of Solo: you see every change to Telitacicept the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in